XML 72 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt - Long-Term Debt from Royalty-Bearing Instrument-December 2012 Financing - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 06, 2012
Feb. 29, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Debt Disclosure [Line Items]          
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount     $ 49,702,000 $ 79,710,000  
Interest expense, non-cash     1,644,000 2,183,000 $ 2,332,000
CPPIB          
Debt Disclosure [Line Items]          
Maximum repayment of future revenue and receivables     52,400,000    
Repayment under agreement     $ 36,200,000    
CPPIB | Scenario Forecast          
Debt Disclosure [Line Items]          
Repayment under agreement   $ 14,200,000      
CPPIB | Vascepa          
Debt Disclosure [Line Items]          
Debt and future repayments percentage of net revenues     10.00%    
BioPharma Debt          
Debt Disclosure [Line Items]          
Amount received at the closing of the agreement $ 100,000,000.0        
Maximum repayment of future revenue and receivables $ 150,000,000.0        
Royalty-Bearing Debt          
Debt Disclosure [Line Items]          
Gain (loss) on change in fair value of derivative liabilities     $ 0 0  
Long-term debt from royalty-bearing instrument, carrying amount net of unamortized discount     49,700,000 79,700,000  
Royalty-Bearing Debt | Cash          
Debt Disclosure [Line Items]          
Interest expense, contractual coupon interest     4,400,000 5,600,000  
Royalty-Bearing Debt | Non Cash          
Debt Disclosure [Line Items]          
Interest expense, non-cash     $ 1,600,000 $ 2,000,000.0